Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE. Brown JR, Eichhorst B, Lamanna N, O'Brien SM, et al. Blood 2024;144:2706-2717.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Brown JR, Eichhorst B, Lamanna N, O'Brien SM, et al. Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE. Blood 2024;144:2706-2717.
PMID: 39316666